Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marken opens new pharmaceutical service depot
The new clinical distribution network to serve the pharmaceutical community has been built on Marken’s current Latin America business which serves more than 1200 clinical research investigator sites
The new clinical distribution network to serve the pharmaceutical community has been built on Marken’s current Latin America business which serves more than 1200 clinical research investigator sites
The study being sponsored by GSK, will involve patients with a positive diagnosis of ALI and will be conducted throughout the US and Canada. The efficacy of the
Mobile Intelligence features superior 360° view of customer interactions, intuitive Graphical User Interface (GUI) that drives high end user adoption. In addition, it comprises modules for account objectives
The primary objectives of the multi-centre, single-blind study are to compare the relative efficacy of the two anti-TNF therapies during short- and long-term treatment (12 and 104 weeks
The Quad contains four Gilead compounds in a complete once-daily, single-tablet regimen which includes elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The MAA for the Quad is supported
As per the agreement, Hua will receive the full preclinical and clinical documentation for Roche’s GKA program, drug product API for RO5305552, and rights to potential back-up compounds.
Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program. Michael J. Fox Foundation for Parkinson’s Research has
The new patent is estimated to provide protection until March 2027. Marshall CEO and president Daniel Gold said the patent represents another important milestone in their efforts to
Pfizer is responsible for the clinical development, manufacturing, and commercialization of the product in the licensed territory, as well as certain non-exclusive territories outside of North America. As
Edarbyclor is a once-daily fixed-dose combination regimen of azilsartan medoxomil and diuretic chlorthalidone. The recommended starting dose of Edarbyclor is 40/12.5 mg and the maximum dose is 40/25